Last reviewed · How we verify
NCT02804776: PROGRESS
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
Completed
Phase 2
Last updated 2 June 2021
What this trial tests
Phase 2 trial testing Gefitinib in Non-small Cell Lung Cancer in 15 participants. Completed in 21 February 2018.
Timeline
27 January 2015
Primary endpoint
21 February 2018
21 February 2018
21 February 2018
Quick facts
| Lead sponsor | National Cancer Centre, Singapore |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 27 January 2015 |
| Primary completion | 21 February 2018 |
| Estimated completion | 21 February 2018 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Gefitinib (gefitinib) — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
National Cancer Centre, Singapore
Who can join
21 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges.
Kalvapudi S, Vedire Y, Yendamuri S, Barbi J. · · 2023 · cited 19× · PMID 38144524 · DOI 10.3389/fonc.2023.1286104 -
An emerging master inducer and regulator for epithelial-mesenchymal transition and tumor metastasis: extracellular and intracellular ATP and its molecular functions and therapeutic potential.
Cao Y, Chen E, Wang X, Song J, et al · · 2023 · cited 18× · PMID 36750864 · DOI 10.1186/s12935-023-02859-0 -
Neoadjuvant treatment of stage IIIA-N2 in <i>EGFR</i>-Mutant/<i>ALK</i>-rearranged non-small cell lung cancer.
Reyes R, Reguart N. · · 2021 · cited 14× · PMID 33569340 · DOI 10.21037/tlcr-20-780 -
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer.
Sa H, Song P, Ma K, Gao Y, et al · · 2019 · cited 9× · PMID 31632066 · DOI 10.2147/ott.s222412 -
Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris MG, Mitsudomi T, Peters S. · · 2023 · cited 3× · PMID 37197636 · DOI 10.21037/tlcr-22-723
Verify or expand the search:
- PubMed search for NCT02804776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gefitinib
Trials testing the same drug.
- NCT03866499 — A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients · Phase 3 · active not recruiting
- NCT04425187 — Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC · Phase 2 · unknown
- NCT04358562 — Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Trea · Phase 2 · unknown
- NCT04239833 — A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer · Phase 3 · unknown
- NCT04143607 — ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC · Phase 3 · active not recruiting
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other National Cancer Centre, Singapore trials
Trials by the same sponsor.
- NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
- NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
- NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
- NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
- NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02804776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
- Last refreshed: 2 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02804776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing